Quarterly ResultMay 13, 2026, 04:03 PM
Journey Medical Q1 Revenue +21% to $16.0M; Net Loss Narrows to $2.2M
AI Summary
Journey Medical Corporation reported a strong first quarter for 2026, with total revenues increasing 21% year-over-year to $16.0 million, primarily driven by robust Emrosi® sales of $6.3 million. The company significantly narrowed its net loss to $2.2 million and achieved positive Adjusted EBITDA of $0.6 million. Journey Medical also strengthened its cash position to $27.2 million and expanded market access for Emrosi® by securing a contract with a major Group Purchasing Organization, now covering approximately 85% of commercial lives.
Key Highlights
- Total revenues increased 21% year-over-year to $16.0 million in Q1 2026.
- Emrosi® revenues grew to $6.3 million in Q1 2026 from $2.1 million in Q1 2025.
- Net loss narrowed to $2.2 million, or $(0.08) per share, from $4.1 million.
- Adjusted EBITDA turned positive at $0.6 million, or $0.02 per share.
- Cash and cash equivalents increased to $27.2 million as of March 31, 2026.
- Emrosi® prescriptions totaled 29,968 in Q1 2026, up from 27,023 in Q4 2025.
- Secured GPO contract for Emrosi®, providing access to approximately 85% of commercial lives.
- Gross margin decreased to 61.0% due to a $1.3 million non-recurring inventory write-down.